	US 11,701,417 B2
	Vaccine formulation to protect against pertussis
Fredrick Heath Damron, Morgantown, WV (US); and Mariette Barbier, Morgantown, WV (US)
Assigned to WEST VIRGINIA UNIVERSITY, Morgantown, WV (US)
Filed by WEST VIRGINIA UNIVERSITY, Morgantown, WV (US)
Filed on Mar. 27, 2020, as Appl. No. 16/832,490.
Claims priority of provisional application 62/824,730, filed on Mar. 27, 2019.
Prior Publication US 2020/0405839 A1, Dec. 31, 2020
Int. Cl. A61K 39/09 (2006.01); A61P 31/04 (2006.01); A61K 39/02 (2006.01); A61K 39/39 (2006.01)

CPC A61K 39/099 (2013.01) [A61K 39/39 (2013.01); A61P 31/04 (2018.01)]

21 Claims

1. A vaccine composition, comprising:

a Bordetella pertussis antigen, wherein the Bordetella pertussis antigen comprises an extracellular pertussis toxoid (PT), the adhesion protein filamentous hemagglutinin (FHA), or a combination thereof; and

an effective adjuvant amount of a 1,3-beta-glucan/1,6-beta-glucan copolymer derived from baker's yeast with a particle size of 3 μm to 4 μm.